RFL Profile
Rafael Holdings, Inc. is a diversified company with interests spanning clinical-stage pharmaceutical development and commercial real estate assets in both the United States and Israel. The company operates through two primary segments: Healthcare and Real Estate. In the Healthcare segment, Rafael Holdings focuses on the development and commercialization of innovative therapies that target the metabolic differences between normal and cancerous cells, aiming to address unmet medical needs in oncology.
The company’s lead therapeutic candidate is CPI-613 (devimistat), a novel drug currently in Phase III clinical trials. CPI-613 is being evaluated for its efficacy in treating metastatic pancreatic cancer and acute myeloid leukemia (AML). This drug represents a significant advancement in cancer treatment, leveraging its unique mechanism of action to potentially improve outcomes for patients with these challenging and aggressive cancers.
In addition to its pharmaceutical ventures, Rafael Holdings holds a portfolio of commercial real estate assets in the United States and Israel. This real estate segment complements the company's healthcare operations by providing a stable revenue stream and diversifying its business interests. The real estate assets include various properties that generate rental income and contribute to the overall financial stability of the company.
Incorporated in 2017 and headquartered in Newark, New Jersey, Rafael Holdings, Inc. has positioned itself at the intersection of cutting-edge pharmaceutical research and strategic real estate investments. The company continues to advance its drug development programs while managing its real estate portfolio to support its long-term growth objectives. With a focus on both innovative therapies and robust asset management, Rafael Holdings aims to create value across its diverse business segments.
|
